Total trials
66
Active
3
Phase 3
29
Total enrollment
91,541
Pipeline matrix
Showing 4 of 4 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Atezolizumab | — | — | — | — | — | 1 | |
| Cemiplimab | — | — | — | — | — | 1 | |
| cemiplimab plus fianlimab | — | — | — | — | — | 1 | |
| cemiplimab + REGN7075 | — | — | — | — | — | 1 |
Next readouts
- 2024-12-31
- 2029-04-17
Top conditions
- Breast Cancer35
- Colorectal Cancer14
- Metastatic Colorectal Cancer4
- Fatigue3
- Metastatic Cancer2
- Breast Neoplasms2
- Rectal Cancer2
- HER2-negative Breast Cancer2
Frequently asked questions about NSABP Foundation Inc
- How many clinical trials does NSABP Foundation Inc have on ClinicalTrials.gov?
- NSABP Foundation Inc is listed as the lead sponsor on 66 clinical trials in ClinicalTrials.gov, 3 of which are currently active (recruiting, enrolling, or ongoing).
- How many of NSABP Foundation Inc's trials are in Phase 3?
- 29 of NSABP Foundation Inc's trials are in Phase 3, spread across 4 active drug programs.
- What therapeutic areas does NSABP Foundation Inc focus on?
- NSABP Foundation Inc's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Colorectal Cancer, Metastatic Colorectal Cancer, Fatigue, Metastatic Cancer.
- When are NSABP Foundation Inc's next clinical trial readouts?
- NSABP Foundation Inc has 2 upcoming primary-completion readouts tracked here; the soonest is “Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo”, expected around 2024-12-31.